GERN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – GERN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Geron securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by May 12, 2025, to serve as lead plaintiff, representing other class members [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Geron made false and misleading statements regarding the market potential of its drug RYTELO, claiming that factors such as lack of awareness among healthcare providers and competition would impair its profitability [4] - It is asserted that Geron's business and financial prospects were overstated, leading to materially false public statements [4]